PWMG
ALNY icon

Prestige Wealth Management Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Prestige Wealth Management Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.5K Sell
201
-25
-11% -$7.54K 0.01% 250
2026
Q1 		$74.8K Buy
226
+53
+31% +$18K 0.01% 224
2025
Q4 		$68.8K Sell
173
-11
-6% -$4.87K 0.01% 229
2025
Q3 		$83.9K Hold
184
– – 0.02% 225
2025
Q2 		$60K Sell
184
-132
-42% -$36.5K 0.01% 239
2025
Q1 		$85.3K Hold
316
– – 0.02% 208
2024
Q4 		$74.4K Sell
316
-135
-30% -$35.5K 0.02% 222
2024
Q3 		$124K Buy
451
+179
+66% +$46.6K 0.03% 179
2024
Q2 		$66.1K Sell
272
-200
-42% -$31.6K 0.01% 207
2024
Q1 		$70.5K Buy
472
+194
+70% +$32.4K 0.02% 230
2023
Q4 		$53.2K Sell
278
-36
-11% -$6.13K 0.01% 240
2023
Q3 		$55.6K Buy
314
+304
+3,040% +$58K 0.01% 234
2023
Q2 		$1.9K Hold
10
– – ﹤0.01% 772
2023
Q1 		$2K Buy
10
+3
+43% +$631 ﹤0.01% 744
2022
Q4 		$1.66K Sell
7
-30
-81% -$6.4K ﹤0.01% 870
2022
Q3 		$7K Sell
37
-1,480
-98% -$282K ﹤0.01% 473
2022
Q2 		$221K Buy
1,517
+293
+24% +$41.6K 0.06% 127
2022
Q1 		$200K Buy
1,224
+600
+96% +$91.4K 0.05% 141
2021
Q4 		$105K Buy
624
+580
+1,318% +$108K 0.03% 192
2021
Q3 		$9K Buy
44
+14
+47% +$2.63K ﹤0.01% 496
2021
Q2 		$5K Hold
30
– – ﹤0.01% 607
2021
Q1 		$4K Hold
30
– – ﹤0.01% 647
2020
Q4 		$4K Hold
30
– – ﹤0.01% 611
2020
Q3 		$4K Hold
30
– – ﹤0.01% 555
2020
Q2 		$4K Hold
30
– – ﹤0.01% 541
2020
Q1 		$3K Buy
+30
New +$3.46K ﹤0.01% 556

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prestige Wealth Management Group's ALNY Position: Q2 2026 in Review

Prestige Wealth Management Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 11% in Q2 2026, selling an estimated $7.54K and leaving 201 shares worth $60.5K. The position accounts for 0.01% of the portfolio, ranked #250.

Prestige Wealth Management Group first reported a position in ALNY in Q1 2020 and has held it in 26 quarters since. The position peaked at $221K in Q2 2022. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Prestige Wealth Management Group held 201 shares of Alnylam Pharmaceuticals worth $60.5K as of Q2 2026.
  • Prestige Wealth Management Group sold 25 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $7.54K.
  • Alnylam Pharmaceuticals made up 0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #250 holding.
  • Prestige Wealth Management Group first reported a position in Alnylam Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Prestige Wealth Management Group's Alnylam Pharmaceuticals position peaked at $221K in Q2 2022.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.